Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
10H04
- Development stage
- Preclinical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
10H04 is a monoclonal antibody (mAb) developed to target human islet amyloid polypeptide (hIAPP) protofibrils, which are toxic aggregates implicated in the destruction of insulin-producing β cells in Type 2 Diabetes Mellitus (T2D). This mAb is designed to specifically bind to hIAPP protofibrils without interacting with monomeric hIAPP. Preclinical studies in a mouse model of T2D have shown that 10H04 can detect hIAPP protofibrils in serum and pancreatic islets, delay disease progression, and significantly increase overall survival by preserving β cell function and addressing the underlying pathological mechanism of hIAPP aggregation.
02
Targets
Human islet amyloid polypeptide (hIAPP) protofibril
Beyond the preview
Go deeper on 10H04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 10H04.